The drug was well tolerated and showed a trend for clinical improvement associated with lower increases in CD19 + B cells and greater decreases in CXCL13 and MIP-1β from baseline to week four [ 87 ].
← all excerpts
Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis.
1
—
—